Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03743649 · ClinicalTrials.gov registry record · Phase 2

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

A Phase 2 study of Delirium and Metastatic Malignant Neoplasm, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
110
Enrollment target
3
Study locations

NCT03743649 is a Phase 2 study of Delirium and Metastatic Malignant Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 110 participants, below the 886-participant average among 62 other Delirium trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03743649, a Phase 2 study of Delirium and Metastatic Malignant Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
110 participants
Enrollment target
3
Study locations

Study Summary

This phase II/IIII trial studies how well haloperidol and lorazepam work in controlling symptoms of persistent agitated delirium in patients with cancer that has spread to other places in the body undergoing palliative care. Haloperidol and lorazepam may help in controlling symptoms of agitated delirium in patients with cancer and may lessen any distress that their caregivers may be experiencing.

Conditions Studied

Delirium Metastatic Malignant Neoplasm Locally Advanced Malignant Neoplasm Recurrent Malignant Neoplasm

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Placebo
  • OTHER Questionnaire Administration
  • DRUG Haloperidol
  • DRUG Lorazepam

Study Locations (3)

Texas

  • M D Anderson Cancer Center - Houston

Virginia

  • Virginia Commonwealth University/Massey Cancer Center - Richmond

São Paulo

  • Hosptial de Cancer de Barretos - Barretos

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2019-07-17
Est. Completion 2026-12-31
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03743649

The ClinicalTrials.gov registry entry for NCT03743649 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 886-participant average among 62 other Delirium trials with a reported enrollment target (88% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Delirium appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.

NCT03743649 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Texas, Virginia, São Paulo.

Frequently Asked Questions

What is clinical trial NCT03743649 about?

NCT03743649 is a clinical study titled "Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care". This phase II/IIII trial studies how well haloperidol and lorazepam work in controlling symptoms of persistent agitated delirium in patients with cancer that has spread to other places in the body undergoing palliative care. Haloperidol and lorazepam may help in controlling symptoms of agitated deli...

What is the current status of trial NCT03743649?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2019-07-17. Estimated completion is 2026-12-31.

What conditions does trial NCT03743649 study?

This clinical trial studies the following conditions: Delirium, Metastatic Malignant Neoplasm, Locally Advanced Malignant Neoplasm, Recurrent Malignant Neoplasm.

What interventions are being tested in trial NCT03743649?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Placebo (OTHER), Questionnaire Administration (OTHER), Haloperidol (DRUG), Lorazepam (DRUG).

Who is sponsoring clinical trial NCT03743649?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03743649 being conducted?

This trial has 3 study locations across Texas, Virginia, São Paulo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Delirium

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Delirium

All registered trials for this condition

Metastatic Malignant Neoplasm

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.